Onkologische Forschung

    Translational Next Generation Sequencing

    Drivers of melanoma progression under therapy
     (collaboration between Physiological Chemistry, Dermatology, Bioinformatics Unit CCC, Human Genetics, Pathology)


    Our project aims to identify effective driver mutations of melanoma using next generation sequencing of a self-designed melanoma-relevant gene panel, RNA analysis and liquid biopsy. By comprehensive analysis of altered genes on DNA and expression level, we can pinpoint druggable cancer-promoting changes. One focus of the study is the evolution of melanoma progression and altered pathway dependence during the course of conventional melanoma therapy.

    Meierjohann S: Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-017-9659-z. (2017) (epub ahead of print)

    Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M, Meierjohann S: The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget 5:5040-5053 (2014)

    Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R, Meierjohann S: Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. 133:1601-1609 (2013)


    Comprehensive Cancer Center Mainfranken
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359

    Suche Ansprechpartner

    Campus Medizin